Memphasys

Memphasys Net Margin

The Net Profit Margin of Memphasys (MEM.AX) as of Oct 19, 2026 is -1,498.73 %. In the previous year, Net Profit Margin was -937.88 % — a change of 59.80% (lower).

Net Margin

-1,498.73 %

YoY

59.80%

Last updated:

Net Profit Margin of Memphasys is 2026 -1,498.73 % . Net Profit Margin of Memphasys was 2025 -937.88 % . It decreases by 59.80% lower compared to the previous year.

Memphasys's net margin stands at -1,498.7%, up from -7,668.9% several years earlier.

The Memphasys Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2015
-2,953.72 AUD
Jan 1, 2016
-3,400.13 AUD
Jan 1, 2021
-702.86 AUD
Jan 1, 2022
-7,668.94 AUD
Jan 1, 2023
-22,136.61 AUD
Jan 1, 2024
-7,403.37 AUD
Jan 1, 2025
-937.88 AUD
Jan 1, 2026
-1,498.73 AUD
The Memphasys Net Margin history
YEARNet MarginYoY
-1,498.73 %+59.80%
-937.88 %-87.33%
-7,403.37 %-66.56%
-22,136.61 %+188.65%
-7,668.94 %+991.10%
-702.86 %-79.33%
-3,400.13 %+15.11%
-2,953.72 %+554.11%
-451.56 %+22,421.58%
-2.01 %+3.81%
-1.93 %-47.04%
-3.65 %-695.45%
0.61 %-148.46%
-1.26 %-62.96%
-3.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Memphasys Stock analysis

What does Memphasys do? Memphasys Ltd, listed on the Australian Securities Exchange under the ticker MEM.AX, is a life sciences company headquartered in Homebush West, New South Wales. The company went public via an IPO on May 14, 2007. Memphasys operates within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company focuses on developing medical devices, diagnostics, and media for applications in assisted reproduction technology (ART) for both humans and animals. Its product pipeline includes several developments, such as Felix, ROSA, and AI-Port. Felix is a patented, automated device designed to separate high-quality sperm from semen for human in vitro fertilization (IVF) procedures, aiming to avoid DNA damage. ROSA functions as an in vitro diagnostic tool to evaluate semen and blood samples for oxidative stress. AI-Port is a system for storing and transporting animal semen for artificial insemination (AI) in livestock, capable of maintaining semen viability for up to four days without freezing, which is a common practice in standard AI procedures. The company's products target global markets, particularly in the field of reproductive biotechnology, with specific applications in both human and animal reproductive health. Memphasys operates with a focus on innovation in reproductive technology, leveraging proprietary media and diagnostic tools to address challenges in assisted reproduction. Memphasys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Memphasys stock

Net Profit Margin of Memphasys is -1,498.73 % in 2026.

Net Profit Margin of Memphasys changed from -937.88 % to -1,498.73 %, representing a 59.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Memphasys since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Memphasys with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Memphasys

All Key Metrics — Memphasys